Publications
Publications
  • November 2005 (Revised November 2005)
  • Case
  • HBS Case Collection

Massachusetts General Hospital and the Enbrel Royalty

By: David S. Scharfstein and Darren R. Smart
  • Format:Print
  • | Pages:9
ShareBar

Abstract

Massachusetts General Hospital is considering selling its royalty interest in Enbrel, Amgen's blockbuster drug for the treatment of rheumatoid arthritis. In assessing whether to sell, and at what price, the hospital must determine its value to a potential buyer as well as its own value of the royalty income.

Keywords

Valuation; Price; Investment Return; Capital; Value; Revenue; Health Care and Treatment; Health Industry; Biotechnology Industry; Massachusetts

Citation

Scharfstein, David S., and Darren R. Smart. "Massachusetts General Hospital and the Enbrel Royalty." Harvard Business School Case 206-075, November 2005. (Revised November 2005.)

About The Author

David S. Scharfstein

Finance
More Publications

More from the Authors